AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11404233 — intervention group
Group type: EXPERIMENTAL
Intervention: Exendin-4 (0.05 pmol·kg‐1·min‐1)
Number of subjects: 0
Study 11404233 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 0
Study 9715049 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal ileal pouch-anal anastomosis (T-IAA)
Number of subjects: 37
Study 9715049 — intervention group
Group type: COMPARATOR
Intervention: Double-stapled ileal pouch-anal anastomosis (DS-IAA)
Number of subjects: 37
Study 8038353 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg
Number of subjects: 73
Study 8038353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 2923591 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine sulfate (2 mg)
Number of subjects: 4
Study 2923591 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sterile saline)
Number of subjects: 4
Study 31866082 — intervention group
Group type: EXPERIMENTAL
Intervention: New-onset postoperative atrial fibrillation (POAF)
Number of subjects: 551
Study 30278560 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1.0 μg/kg over 10 min) followed by maintenance (0.5 μg/kg/h)
Number of subjects: 40
Study 30278560 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (0.05 mg/kg) followed by dexmedetomidine maintenance (0.5 μg/kg/h)
Number of subjects: 40
Study 28393775 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (1 mcg/kg bolus followed by 1 mcg/kg/h infusion)
Number of subjects: 60
Study 28393775 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil (0.1 mcg/kg bolus followed by 0.1 mcg/h infusion)
Number of subjects: 60
Study 26152838 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine hydrochloride
Number of subjects: 20
Study 26152838 — intervention group
Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 20
Study 23207730 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein toothpaste
Number of subjects: 16
Study 23207730 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein toothpaste
Number of subjects: 16
Study 23207730 — intervention group
Group type: COMPARATOR
Intervention: Non-protein (placebo) toothpaste
Number of subjects: 16
Study 23207730 — intervention group
Group type: COMPARATOR
Intervention: Water brushing
Number of subjects: 16
Study 21613795 — intervention group
Group type: EXPERIMENTAL
Intervention: HD200 (200 mg/dl)
Number of subjects: 23
Study 21613795 — intervention group
Group type: COMPARATOR
Intervention: HD100 (100 mg/dl)
Number of subjects: 23
Study 18362317 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of dental amalgam only
Number of subjects: 90
Study 18362317 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal in combination with a 'biological detoxification' therapy with high doses of vitamins and trace elements
Number of subjects: 90
Study 18362317 — intervention group
Group type: COMPARATOR
Intervention: Health promotion program without removal of dental amalgam
Number of subjects: 90
Study 18362317 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal groups (both removal and removal-plus)
Number of subjects: 90
Study 16523309 — intervention group
Group type: EXPERIMENTAL
Intervention: DISA SPECT (with 99mTc-sestamibi and 18F-FDG)
Number of subjects: 47
Study 16523309 — intervention group
Group type: EXPERIMENTAL
Intervention: PET (with 13N-ammonia and 18F-FDG)
Number of subjects: 47
Study 16523309 — intervention group
Group type: EXPERIMENTAL
Intervention: DISA SPECT
Number of subjects: 47
Study 16523309 — intervention group
Group type: EXPERIMENTAL
Intervention: PET
Number of subjects: 47
Study 15000440 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA (14.4 g/day)
Number of subjects: 22
Study 15000440 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isocaloric)
Number of subjects: 22
Study 15000440 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA (14.4 g/day) for 30 days
Number of subjects: 22
Study 11061609 — intervention group
Group type: EXPERIMENTAL
Intervention: I-CHOPE regimen (doxorubicin 10 mg/m2/day, vincristine 0.28 mg/m2/day, etoposide 48 mg/m2/day, cyclophosphamide 750 mg/m2 on day 6, prednisone 100 mg/day on days 1-5)
Number of subjects: 29
Study 9569783 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined root surface conditioning with tetracycline HCI, fibrin sealing system, guided tissue regeneration procedure and coronal sliding flap application
Number of subjects: 10
Study 9569783 — intervention group
Group type: COMPARATOR
Intervention: Coronal sliding flap operation (Control group)
Number of subjects: 10
Study 8096670 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS
Number of subjects: 20
Study 8096670 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 20
Study 8096670 — intervention group
Group type: COMPARATOR
Intervention: Beta blockers alone
Number of subjects: 20
Study 3927954 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 micrograms kg‐1 extradural
Number of subjects: 18
Study 3927954 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 micrograms kg‐1 extradural
Number of subjects: 18
Study 3927954 — intervention group
Group type: COMPARATOR
Intervention: 15 micrograms kg‐1 i.m.
Number of subjects: 18
Study 31838498 — intervention group
Group type: EXPERIMENTAL
Intervention: TTV viremia in Down syndrome (DS) population
Number of subjects: 1813
Study 31838498 — intervention group
Group type: COMPARATOR
Intervention: TTV viremia in offspring of centenarians (GO) population
Number of subjects: 1813
Study 31838498 — intervention group
Group type: COMPARATOR
Intervention: TTV viremia in spouses of GO (SGO) population
Number of subjects: 1813
Study 31838498 — intervention group
Group type: COMPARATOR
Intervention: TTV viremia in randomly recruited age‐stratified individuals (RASIG) population
Number of subjects: 1813
Study 31838498 — intervention group
Group type: EXPERIMENTAL
Intervention: TTV loads ≥4log copies/ml in males
Number of subjects: 1813
Study 31838498 — intervention group
Group type: COMPARATOR
Intervention: TTV loads in the general population
Number of subjects: 1813
Study 28193583 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 mg nicotine patch
Number of subjects: 17
Study 28193583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 26026105 — intervention group
Group type: EXPERIMENTAL
Intervention: AGO-positive group (n=139)
Number of subjects: 209
Study 26026105 — intervention group
Group type: COMPARATOR
Intervention: AGO-negative group (n=70)
Number of subjects: 209
Study 26026105 — intervention group
Group type: EXPERIMENTAL
Intervention: AGO-positive patients with complete resection
Number of subjects: 209
Study 26026105 — intervention group
Group type: COMPARATOR
Intervention: AGO-negative patients with complete resection
Number of subjects: 209
Study 26026105 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups after complete resection
Number of subjects: 209
Study 26026105 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 209
Study 23350920 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes self-management interventions
Number of subjects: 85
Study 21452066 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted colectomy (LAC)
Number of subjects: 449
Study 21452066 — intervention group
Group type: COMPARATOR
Intervention: Open colectomy
Number of subjects: 449
Study 21452066 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline support
Number of subjects: 449
Study 21452066 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline outlook
Number of subjects: 449
Study 19647928 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis (rtPA)
Number of subjects: 156
Study 17370487 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint injection at cervical Jiaji points and routine acupuncture
Number of subjects: 70
Study 17370487 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture
Number of subjects: 70
Study 12740311 — intervention group
Group type: COMPARATOR
Intervention: Alcohol-displacement (A) diet (1.5 g/kg alcohol displacing CHO energy from control)
Number of subjects: 15
Study 12740311 — intervention group
Group type: COMPARATOR
Intervention: Alcohol + CHO (AC) diet (Control + 1.5 g/kg alcohol)
Number of subjects: 15
Study 12740311 — intervention group
Group type: EXPERIMENTAL
Intervention: Control (C) diet (meals providing carbohydrate (CHO) of 1.75 g/kg)
Number of subjects: 15
Study 10225813 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphasalazine (SSZ)
Number of subjects: 200
Study 10225813 — intervention group
Group type: COMPARATOR
Intervention: Auranofin (AUR)
Number of subjects: 200
Study 8648356 — intervention group
Group type: EXPERIMENTAL
Intervention: CVUft group (cisplatin 50 mg/m2, vindesine 2 to 3 mg/kg for three courses, and 1-year oral administration of tegafur plus uracil 400 mg/kg)
Number of subjects: 323
Study 8648356 — intervention group
Group type: EXPERIMENTAL
Intervention: Uft group (1-year oral administration of UFT 400 mg/kg)
Number of subjects: 323
Study 8648356 — intervention group
Group type: COMPARATOR
Intervention: Control group (surgical treatment only)
Number of subjects: 323
Study 8648356 — intervention group
Group type: COMPARATOR
Intervention: CVUft group vs Control group
Number of subjects: 323
Study 8648356 — intervention group
Group type: COMPARATOR
Intervention: Uft group vs Control group
Number of subjects: 323
Study 8648356 — intervention group
Group type: COMPARATOR
Intervention: CVUft group vs Control group (Cox model)
Number of subjects: 323
Study 8648356 — intervention group
Group type: COMPARATOR
Intervention: Uft group vs Control group (Cox model)
Number of subjects: 323
Study 1984192 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (n = 25)
Number of subjects: 47
Study 1984192 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 22)
Number of subjects: 47
Study 6135989 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (324 mg in buffered solution daily for 12 weeks)
Number of subjects: 1266
Study 6135989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1266
Study 3000793 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 240 mg
Number of subjects: 6
Study 3000793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31047591 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (Avastin)
Number of subjects: 47
Study 31047591 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone implant (Ozurdex)
Number of subjects: 47
Study 27555178 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 1 μg/kg
Number of subjects: 0
Study 27555178 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 μg/kg
Number of subjects: 0
Study 27555178 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 μg/kg
Number of subjects: 0
Study 27555178 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 24121920 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-oral electrostimulator (GenNarino)
Number of subjects: 6
Study 24121920 — intervention group
Group type: COMPARATOR
Intervention: Sham-device
Number of subjects: 6
Study 22976167 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergonomic intervention (hand air pipe)
Number of subjects: 100
Study 22976167 — intervention group
Group type: COMPARATOR
Intervention: Control (standard blowing pipe)
Number of subjects: 100
Study 19297221 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lorazepam (0.1 mg/kg)
Number of subjects: 178
Study 19297221 — intervention group
Group type: COMPARATOR
Intervention: Intravenous diazepam (0.2 mg/kg) - phenytoin (18 mg/kg) combination
Number of subjects: 178
Study 18684843 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training (twice-weekly 50-min sessions for 12 weeks)
Number of subjects: 34
Study 18684843 — intervention group
Group type: COMPARATOR
Intervention: Control group (no physical training)
Number of subjects: 34
Study 16147845 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatiotemporal Image Correlation (STIC) technique for obtaining LVOT images
Number of subjects: 20
Study 16147845 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatiotemporal Image Correlation (STIC) technique for obtaining RVOT images
Number of subjects: 20
Study 16147845 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraobserver agreement analysis for LVOT images
Number of subjects: 20
Study 14705720 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (40 mg subcutaneously once daily for 10 days)
Number of subjects: 170
Study 14705720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 10877418 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-strength gadodiamide (0.11-0.25 mmol/kg)
Number of subjects: 25
Study 10877418 — intervention group
Group type: COMPARATOR
Intervention: Half-strength iodinated contrast material (300 mg/mL iodine)
Number of subjects: 25
Study 8976353 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Closure (PC)
Number of subjects: 399
Study 8976353 — intervention group
Group type: EXPERIMENTAL
Intervention: Polytetrafluoroethylene Patch Closure (PTFE‐PC)
Number of subjects: 399
Study 8976353 — intervention group
Group type: EXPERIMENTAL
Intervention: Vein Patch Closure (SVP and JVP)
Number of subjects: 399
Study 8976353 — intervention group
Group type: COMPARATOR
Intervention: All patching (vein and PTFE)
Number of subjects: 399
Study 8976353 — intervention group
Group type: COMPARATOR
Intervention: Vein Patch Closure
Number of subjects: 399
Study 8976353 — intervention group
Group type: EXPERIMENTAL
Intervention: Vein Patch Closure (SVP)
Number of subjects: 399
Study 8976353 — intervention group
Group type: EXPERIMENTAL
Intervention: Vein Patch Closure (JVP)
Number of subjects: 399
Study 1468239 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg etodolac SR once daily for 4 weeks
Number of subjects: 64
Study 1468239 — intervention group
Group type: COMPARATOR
Intervention: 100 mg diclofenac SR
Number of subjects: 64
Study 6478435 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal therapy (2 courses of chemotherapy: cisplatin 2 mg/kg; methotrexate 280‐560 mg/m2 with leucovorin rescue; bleomycin 30 mu X 3) followed by radiation therapy and surgery
Number of subjects: 58
Study 6478435 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal therapy
Number of subjects: 58
Study 6478435 — intervention group
Group type: COMPARATOR
Intervention: Combined therapy (preoperative radiation therapy followed by surgery)
Number of subjects: 58
Study 6478435 — intervention group
Group type: COMPARATOR
Intervention: Combined therapy
Number of subjects: 58
Study 6478435 — intervention group
Group type: COMPARATOR
Intervention: Responses to therapy in combined therapy
Number of subjects: 58
Study 31067089 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-way SMS with a nurse
Number of subjects: 260
Study 31067089 — intervention group
Group type: COMPARATOR
Intervention: Control (no SMS)
Number of subjects: 260
Study 30383859 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood sexual abuse (CSA)
Number of subjects: 1002
Study 30383859 — intervention group
Group type: COMPARATOR
Intervention: Concurrently experiencing 2 or more syndemic factors
Number of subjects: 1002
Study 27175601 — intervention group
Group type: EXPERIMENTAL
Intervention: High-cadence (HC) interval training (20% above FCC)
Number of subjects: 16
Study 27175601 — intervention group
Group type: COMPARATOR
Intervention: Low-cadence (LC) interval training (20% below FCC)
Number of subjects: 16
Study 27175601 — intervention group
Group type: EXPERIMENTAL
Intervention: High-cadence (HC) interval training
Number of subjects: 16
Study 27175601 — intervention group
Group type: COMPARATOR
Intervention: Low-cadence (LC) interval training
Number of subjects: 16
Study 25306809 — intervention group
Group type: EXPERIMENTAL
Intervention: TUERP
Number of subjects: 630
Study 25306809 — intervention group
Group type: COMPARATOR
Intervention: TURP
Number of subjects: 630
Study 25306809 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 630
Study 22869829 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (4 or 5 mg daily for 12 weeks)
Number of subjects: 46
Study 22869829 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 12 weeks)
Number of subjects: 46
Study 20331663 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster care
Number of subjects: 169
Study 20331663 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 169
Study 20331663 — intervention group
Group type: EXPERIMENTAL
Intervention: Never-institutionalized group
Number of subjects: 169
Study 18559683 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer training and Internet usage
Number of subjects: 191
Study 18559683 — intervention group
Group type: COMPARATOR
Intervention: Training-no intervention
Number of subjects: 191
Study 18559683 — intervention group
Group type: COMPARATOR
Intervention: No training-no intervention
Number of subjects: 191
Study 18559683 — intervention group
Group type: COMPARATOR
Intervention: No interest in computer use
Number of subjects: 191
Study 16019363 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg
Number of subjects: 80
Study 16019363 — intervention group
Group type: COMPARATOR
Intervention: Continuous combined CEE/MPA 0.625 mg/day and 5 mg/day
Number of subjects: 80
Study 12447954 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 200 mg/day PO
Number of subjects: 186
Study 12447954 — intervention group
Group type: COMPARATOR
Intervention: Low-dose amphotericin B 0.2 mg/kg/day IV
Number of subjects: 186
Study 10485779 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir (200 mg three times on the first day and 300 mg three times on the second day)
Number of subjects: 12
Study 10485779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8765815 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide aqueous nasal spray (220 micrograms or 440 micrograms)
Number of subjects: 64
Study 8765815 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone (10 mg)
Number of subjects: 64
Study 8765815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 1931395 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.42 mg kg‐1 i.v. followed by an infusion of midazolam 0.125 mg kg‐1 for 1 h
Number of subjects: 8
Study 1931395 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 8
Study 1931395 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone (control)
Number of subjects: 8
Study 6808553 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 16
Study 6808553 — intervention group
Group type: COMPARATOR
Intervention: Control (non-anxious subjects)
Number of subjects: 16
Study 31201146 — intervention group
Group type: EXPERIMENTAL
Intervention: KAASER (500 mg, three times a day for 2 weeks)
Number of subjects: 106
Study 31201146 — intervention group
Group type: COMPARATOR
Intervention: Dimethicone (500 mg, three times a day for 2 weeks)
Number of subjects: 106
Study 31201146 — intervention group
Group type: COMPARATOR
Intervention: Placebo (500 mg, three times a day for 2 weeks)
Number of subjects: 106
Study 28385948 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartMate 3 (HM3) LVAS
Number of subjects: 289
Study 28385948 — intervention group
Group type: COMPARATOR
Intervention: HeartMate II (HMII) LVAS
Number of subjects: 289
Study 26509986 — intervention group
Group type: EXPERIMENTAL
Intervention: rhPDGF‐BB/βTCP with guided bone regeneration (GBR)
Number of subjects: 14
Study 26509986 — intervention group
Group type: COMPARATOR
Intervention: Conventional implant placement
Number of subjects: 14
Study 24021603 — intervention group
Group type: EXPERIMENTAL
Intervention: Biorhythmically defined vasomotion stimulation
Number of subjects: 0
Study 24021603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21251359 — intervention group
Group type: EXPERIMENTAL
Intervention: CCERW clinical prediction rule
Number of subjects: 539
Study 21251359 — intervention group
Group type: EXPERIMENTAL
Intervention: CCERW
Number of subjects: 539
Study 21251359 — intervention group
Group type: COMPARATOR
Intervention: PSI, CURB65, CRB65
Number of subjects: 539
Study 19898698 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose atorvastatin (80 mg/day)
Number of subjects: 8888
Study 19898698 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose simvastatin (20 mg/day to 40 mg/day)
Number of subjects: 8888
Study 17123915 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride-containing materials (e.g., Fuji IX - FIX)
Number of subjects: 108
Study 17123915 — intervention group
Group type: COMPARATOR
Intervention: Control (C) and other fluoride-containing materials (F, H, V)
Number of subjects: 108
Study 17123915 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride release from FIX
Number of subjects: 108
Study 17123915 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride release from CF
Number of subjects: 108
Study 14701770 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary dissection
Number of subjects: 658
Study 14701770 — intervention group
Group type: COMPARATOR
Intervention: Axillary radiotherapy
Number of subjects: 658
Study 12212341 — intervention group
Group type: EXPERIMENTAL
Intervention: Glynase Prestabs (Group A)
Number of subjects: 30
Study 12212341 — intervention group
Group type: COMPARATOR
Intervention: Generic tablets (Group A)
Number of subjects: 30
Study 12212341 — intervention group
Group type: EXPERIMENTAL
Intervention: Glynase Prestabs (Group B)
Number of subjects: 30
Study 12212341 — intervention group
Group type: COMPARATOR
Intervention: Generic tablets (Group B)
Number of subjects: 30
Study 9258217 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin, 0.2 mg/mL, applied for 2 minutes
Number of subjects: 300
Study 9258217 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin, 0.4 mg/mL, applied for 4 minutes
Number of subjects: 300
Study 9258217 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin, 0.4 mg/mL, applied for 2 minutes
Number of subjects: 300
Study 9258217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 8438713 — intervention group
Group type: EXPERIMENTAL
Intervention: Excimer laser coronary angioplasty (ELCA)
Number of subjects: 53
Study 8438713 — intervention group
Group type: EXPERIMENTAL
Intervention: Excimer laser coronary angioplasty (ELCA) followed by adjunctive PTCA
Number of subjects: 53
Study 3553759 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol and atropine
Number of subjects: 12
Study 3553759 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine and histamine
Number of subjects: 12